These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12003391)

  • 21. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
    Nelson M; Cicuttini F
    Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
    [No Abstract]   [Full Text] [Related]  

  • 22. [Rofecoxib-induced aquagenic edema with puckering of the palms of the hands: the first case].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):813. PubMed ID: 14576620
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient empowerment: rofecoxib revisited.
    Tannenbaum H
    J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
    [No Abstract]   [Full Text] [Related]  

  • 26. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 28. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythema multiforme due to rofecoxib.
    Sarkar R; Kaur C; Kanwar AJ
    Dermatology; 2002; 204(4):304-5. PubMed ID: 12077530
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.
    Strand V; Hochberg MC
    Arthritis Rheum; 2002 Aug; 47(4):349-55. PubMed ID: 12209478
    [No Abstract]   [Full Text] [Related]  

  • 33. Rofecoxib does not adversely affect skin graft survival in a rat model.
    Miller Q; Losken A; Harre JG; Bird ME
    Curr Surg; 2004; 61(2):227-30. PubMed ID: 15051270
    [No Abstract]   [Full Text] [Related]  

  • 34. The law. Vioxx verdict: too little or too much science?
    Lawler A
    Science; 2005 Sep; 309(5740):1481. PubMed ID: 16141043
    [No Abstract]   [Full Text] [Related]  

  • 35. Rofecoxib: a possible cause of acute colitis.
    Freitas J; Farricha V; Nascimento I; Borralho P; Paramés A
    J Clin Gastroenterol; 2002 Apr; 34(4):451-3. PubMed ID: 11907361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rofecoxib-induced upper gastrointestinal bleeding].
    de La Serna Higuera C; Rodríguez-Gómez SJ; Martín Arribas MI; Martínez Moreno J
    Med Clin (Barc); 2002 Feb; 118(6):238; author reply 239. PubMed ID: 11864550
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute cholestatic hepatitis associated with long-term use of rofecoxib.
    Papachristou GI; Demetris AJ; Rabinovitz M
    Dig Dis Sci; 2004 Mar; 49(3):459-61. PubMed ID: 15139498
    [No Abstract]   [Full Text] [Related]  

  • 39. Lichenoid drug eruption probably associated with rofecoxib.
    Abu-Shraie NA; Alfadley AA
    Ann Pharmacother; 2004 May; 38(5):795-8. PubMed ID: 15026562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.